NeuroVia, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.neurovia-inc.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
- Conditions
- X-Linked Adrenoleukodystrophy
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- NeuroVia, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03278899
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
Phase 1
Withdrawn
- Conditions
- X-Linked Adrenoleukodystrophy
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- NeuroVia, Inc.
- Registration Number
- NCT03196765
- Locations
- 🇦🇷
Hospital Austral, Buenos Aires, Argentina
🇦🇷Hospital General de ninos Pedro de Elizalde, Buenos Aires, Argentina
🇦🇺Monash Health, Clayton, Victoria, Australia
News
No news found